Skip to main content
. 2012 Jul 19;6(1):125–134. doi: 10.1242/dmm.009167

Fig. 4.

Fig. 4.

Treatment-dependent human IgG and IgE secretion. (A,B) PBMC derived from three different patients suffering from AD and from two healthy volunteers (non-AD) were analyzed in vitro and in vivo with respect to their capacity to secrete human IgG (A) and IgE (B). Sample sizes: in vitro AD n=3; in vitro non-AD n=2; in vivo AD after treatment with IL-4 n=5, NaCl n=4, ethanol n=13 or oxazolone n=12; in vivo non-AD after treatment with IL-4 n=8, NaCl n=4, ethanol n=8 or oxazolone n=9. (A) hIgG secretion. IL-4 had moderate effects on IgG levels in vitro and in vivo, whereas ethanol and oxazolone induced the secretion of hIgG. (B) hIgE secretion. IL-4 induced IgE secretion in vitro in the AD group and in one donor of the non-AD group, whereas in vivo IL-4 failed to induce hIgE in both groups. Ethanol and oxazolone induced hIgE secretion in the AD group but not the non-AD group. IgE levels in the four different groups were significantly different. Kruskal-Wallis test followed by multiple comparisons revealed that the oxazolone- and ethanol-treated groups were significantly different to the IL-4-treated group (P=0.01 and P=0.01, respectively).